(AOF) – Quantum Genomics announces that it is ending the exclusive negotiation initiated with Vistacare Medical and announced on July 20. The biotech specialist in cardiovascular diseases believes that “the financial outlook and the difficulties linked to the fragmented shareholding” of Vistacare Medical “do not allow the planned operation to be carried out while preserving the interests of its own shareholders”. Quantum Genomics announces that it is resuming its discussions with unlisted HealthTech companies that meet its selection criteria.
These criteria are “a major field of activity, an innovative and differentiating project, know-how that can be replicated internationally, an efficient team that complements that of Quantum Genomics”.
The biotech’s objective is to “relaunch a business project around its assets, namely its cash flow to date of 4.5 million euros, including 2.5 million euros of Research Tax Credit, its listing in stock market and the know-how of its management”.
Quantum Genomics will publish its accounts for the first half of 2023 on October 24, 2023.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
